ALS Untangled says evidence is insufficient to recommend lunasin for ALS
Original source
Lunasin (opens in a new tab)ALS Untangled found that lunasin has potentially relevant mechanisms and appears reasonably safe, but concluded there is not enough evidence to recommend it for people with ALS. The review identified only one report of improvement that it could independently validate, involving a person with atypical ALS features and a history of myasthenia gravis.
Why this matters
People with ALS should not assume lunasin is an effective treatment based on current evidence. The review suggests that a small pilot trial using confirmed ALS diagnoses and validated outcome measures would be needed before its effects can be assessed more reliably.
Limitations and context
This is an expert review from 2014, not a clinical trial. Evidence was limited to one independently validated improvement report, and that person had a history of myasthenia gravis, which can cause weakness to improve spontaneously. Some forms of lunasin were described as expensive.